{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=12",
    "query": {
      "intervention": "Combination 400",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 1062,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T21:09:20.168Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05571969",
      "title": "Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "2X-121 600 mg",
          "type": "DRUG"
        },
        {
          "name": "2X-121 800 mg",
          "type": "DRUG"
        },
        {
          "name": "2X-121 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "2X-121 + 300 mg dovitinib",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "2X-121 + 400 mg dovitinib",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "2X-121 + 500 mg dovitinib",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Allarity Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2023-03-08",
      "completion_date": "2024-10-07",
      "has_results": true,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 3,
      "location_summary": "Huntersville, North Carolina • Cleveland, Ohio • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05571969"
    },
    {
      "nct_id": "NCT03802227",
      "title": "A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Moderate to Severe Chronic Pain"
      ],
      "interventions": [
        {
          "name": "NKTR-181",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-10-22",
      "completion_date": "2020-01-03",
      "has_results": true,
      "last_update_posted_date": "2021-07-08",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03802227"
    },
    {
      "nct_id": "NCT01283334",
      "title": "A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Cancer of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "RAD001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-01",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2014-12-04",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283334"
    },
    {
      "nct_id": "NCT04624204",
      "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab 200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab 400 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab placebo (saline)",
          "type": "DRUG"
        },
        {
          "name": "Olaparib 300 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Olaparib matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Etoposide 100 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Platinum, investigator's choice",
          "type": "DRUG"
        },
        {
          "name": "Standard Thoracic Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Prophylactic Cranial Irradiation (PCI)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 672,
      "start_date": "2020-12-08",
      "completion_date": "2027-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 35,
      "location_summary": "Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04624204"
    },
    {
      "nct_id": "NCT06295809",
      "title": "A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell",
        "Skin Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intismeran autogene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2024-04-18",
      "completion_date": "2026-03-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • Newport Beach, California • Palo Alto, California + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06295809"
    },
    {
      "nct_id": "NCT01026012",
      "title": "Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiac Function"
      ],
      "interventions": [
        {
          "name": "regadenoson",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-12",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2022-08-02",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 1,
      "location_summary": "Westminster, Maryland",
      "locations": [
        {
          "city": "Westminster",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01026012"
    },
    {
      "nct_id": "NCT01773408",
      "title": "A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelogenous Leukemia, Acute"
      ],
      "interventions": [
        {
          "name": "RO5503781 MBP",
          "type": "DRUG"
        },
        {
          "name": "RO5503781 SDP",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2013-02",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-01-25",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Valhalla, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01773408"
    },
    {
      "nct_id": "NCT02378935",
      "title": "Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "VOX",
          "type": "DRUG"
        },
        {
          "name": "SOF/VEL",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2015-02-17",
      "completion_date": "2016-04-12",
      "has_results": true,
      "last_update_posted_date": "2020-03-06",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 31,
      "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02378935"
    },
    {
      "nct_id": "NCT00800735",
      "title": "A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Pegylated-interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-04",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-10-30",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • San Francisco, California • Lutherville, Maryland + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00800735"
    },
    {
      "nct_id": "NCT07217379",
      "title": "The DART DELIVER-02 Study",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV (Human Immunodeficiency Virus)"
      ],
      "interventions": [
        {
          "name": "MGD020",
          "type": "DRUG"
        },
        {
          "name": "MGD014",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Temporary treatment interruption",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-10-02",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-31T21:09:20.168Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07217379"
    }
  ]
}